Assessing and Controlling Potency of Vector and Drug Product for Chimeric Antigen Receptor T Cells
|
|
- Adam Stanley
- 6 years ago
- Views:
Transcription
1 Assessing and Controlling Potency of Vector and Drug Product for Chimeric Antigen Receptor T Cells David M, Hambly, Ph.D. Director, Analytical Development April 4th, 2016
2 Forward Looking Statements/Safe Harbor To the extent statements contained in this presentation are not descriptions of historical facts regarding Kite Pharma, Inc. ( Kite, we, us, or our ), they are forward-looking statements reflecting management s current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry s actual results, levels or activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by words such as anticipate, believe, could, estimate, expect, intend, may, plan, potential, predict, project, should, will, would or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forwardlooking statements contained in this presentation include, but are not limited to, statements regarding: (i) the success and timing of our product development activities; (ii) the ability to effectively manufacture T cell product candidates; and (iii) our and our partners ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission (SEC), including without limitation in its Annual Report on Form 10-K filed with the SEC on February 29, Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 2
3 Harnessing the Power of a Patient s Own Immune System to Target and Kill Cancer Cells ENGINEERED AUTOLOGOUS CELL THERAPY (eact ) 3
4 Dual Platform Targets Both Hematological and Solid Cancers Chimeric Antigen Receptor (CAR) Targets molecules on the cell surface T Cell Receptor (TCR) Targets molecules at or below the cell surface 4
5 Overview of the Manufacturing Process Clinical Center Apheresis product Ship for Manufacturing Enrich for T cells Ficoll separation of PBMC Manufacturing Site T cell Activation Retroviral Transduction Gentle stimulation with anti-cd3 Ab Natural co-stimulatory signals from Monocytes and B cells Introduce CAR gene Clinical Center T cell Expansion Harvest / Freeze Final Product Achieve dose Test product Prepare KTE-C19 Ship to Patient 5
6 Distinct Features of T Cell Products Multi-step process Variability risk due to: Raw materials and supplies Patient cells (e.g., apheresis product) Production process Analytical methods depend on bioassay and Flow Cytometry Multiple bioassays may be required to assess the product 6
7 Final Product Phenotype is Variable Healthy Subjects Lymphoma Subjects 100% 100% Teff Tem Tcm Naïve Donor Patient % 100% CD4 CD8 Donor Patient Variability in the phenotype may impact analytical results 7
8 CAR-T Product Candidates have Distinct Mechanisms of Action Retroviral Vector Manufacturing of effective CAR T cells involves important biological functions: 1. Retroviral vector with consistent transducing potency 2. Infection, reverse transcription and integration of the CAR sequence into the cellular genome 3. Expression and localization of functional CAR in the plasma membrane 4. Antigen induced stimulation of the CAR T cell 5. Cytotoxicity directed towards antigen-positive cells 8
9 % Transduction Retroviral Vector Potency Assesses CAR Expression Measured in Transducing units/ml Potency is used to determine titer: (% CAR expressing cells) * (total number of cells) / Volume of Vector used % Transduction Titer Vector Quantity Linear Transduction = Titer Vector potency is used to measure titer at limiting dilutions 9
10 % Transduced Vector Potency Using PBMCs Assessing Potency: Donor derived PBMCs Limited number of cells Minimal dilutions Analysis replicates Donor variability may require donor qualification PBMC Method Vector Quantity An effective clinical method to assess vector potency 10
11 % Transduced Vector Potency Using a Stable T Cell Line Ideal method to assess potency: A robust, stable cell line banked to single-use vials, demonstrated intermediate precision At least 3 measurements, in replicate, across the linear range to average biological variability The capability to measure high and low titer samples Vector Quantity Banked cells can enable increased range, increased replicates, improved throughput and eliminate donor variability 11
12 CAR-T Product Candidates have Distinct Mechanisms of Action Final Product: Transduced Patient T Cells Manufacturing of effective CAR T cells involves numerous biological functions: 1. Retroviral vector with consistent transducing potency 2. Infection, reverse transcription and integration of vector RNA into the cellular genome 3. Expression and localization of functional CAR in the plasma membrane 4. Antigen induced stimulation of the CAR T cell 5. Cytotoxicity directed towards antigen-positive cells 12
13 Assessing T Cell Final Product Transduction Integrated Vector Copy Number: Quantitative PCR result in copies per cell Average of all cells in the sample Correlated to % Transduction Integration assesses product transduction 13
14 CAR Intensity CAR Intensity Final Product Potency: % CAR Expressing T Cells Flow cytometry quantitates the percentage of T cells expressing the CAR. Dose is a defined number of transduced T cells Untransduced Transduced Anti-CD3 mab fluorophore CAR specific fluorophore Utd CAR CD3 Intensity CD3 Intensity % CAR T cells x Total number of cells enables dosing 14
15 % Transduced Flow Cytometry for % Transduction: Validation Strategy Linearity and Accuracy can be assessed by mixing transduced and untransduced cells R² = LOQ can be assessed: 1. ~ N x std dev + background from untransduced cells 2. Mix transduced and untransduced at a defined level. Validate reproducible quantitation of the sample Ratio of Transduced to Untransduced Validate relevant performance parameters 15 15
16 Final Product Potency: Cytokine Release is Dependent on CAR Response to Antigen Antigen Negative Antigen Positive Antigen Negative Antigen Positive Cytokine release is widely used as a surrogate for function 16
17 Final Product Potency: Quantitative Cytokine ELISA Co-Culturing CAR and Antigen Positive Cells Negative controls demonstrate low activity without antigen, or in the absence of the CAR transduction CAR Expressing + Antigen = Strong cytokine signal CAR Expressing, no Antigen = Low signal CAR + ve CAR - ve Untransduced + Antigen = Low signal Untransduced, no Antigen = Low signal UT + ve UT - ve Potent cells release cytokines upon co-culture with antigen 17
18 Future Thoughts: Understanding Method Variability To control method performance through trending, consider external controls Example: Cytokine ELISA quantitation after culturing product and antigen positive cells ELISA uses an external control independent from the std curve Frozen qualified cytokine expressing cells to confirm the antigen positive cells are consistent Example: Flow cytometry to quantitate % transduction Stable transduced and banked cell line qualified to confirm staining and counting were controlled Ensure an ongoing supply of qualified external controls 18
19 Future Thoughts New reference standards should be qualified Use side-by-side testing in bioassays, and ideally orthogonal methods to understand the performance of the current and proposed RS External controls require qualification Consideration should be given to stability and supply Bioassays are key to the product and process control. Carefully consider the entire scope of the method lifecycle and method impacts. 19
20 Acknowledgements Product Sciences Marc Better Emily Lowe Quality Control Prentice Curry Kanti Thirumoorthy Ken Murray Translational Research John Rossi Yueh-wei Shen Heba Nowyhed 20
Comparability Studies for Autologous Cell Therapy Products. Chris Shen July, 2017
Comparability Studies for Autologous Cell Therapy Products Chris Shen July, 2017 Forward Looking Statements/Safe Harbor To the extent statements contained in this presentation are not descriptions of historical
More informationChallenges associated with supply to larger patients populations: Elements of the CTL019 experience
Cell and Gene Therapy Challenges associated with supply to larger patients populations: Elements of the CTL019 experience Daniel Stark Head External Supply Cell- and Gene Therapies Development and Manufacturing
More informationThe tetravalent bispecific NK-cell engaging antibody AFM13 (CD30/CD16A) engages and primes innate immune cells for anti-cancer immunity
The tetravalent bispecific NK-cell engaging antibody AFM13 (CD30/CD16A) engages and primes innate immune cells for anti-cancer immunity Martin Treder, PhD Affimed GmbH AACR Annual Meeting 2017 Forward-looking
More informationPrioritization of Neoantigens without Predictions: Comprehensive T cell Screening using ATLAS
Prioritization of Neoantigens without Predictions: Comprehensive T cell Screening using ATLAS Jessica Baker Flechtner, PhD CSO, Genocea Biosciences 15 November 2016 1 Safe Harbor Statement This presentation
More informationADCC Reporter Bioassay: A Novel, Bioluminescent Cell-Based Assay for Quantifying Fc Effector Function of Antibodies
ADCC Reporter Bioassay: A Novel, Bioluminescent Cell-Based Assay for Quantifying Fc Effector Function of Antibodies Richard Somberg, Ph.D. October 2012 Outline Introduction to ADCC Problem with classic
More informationResearch Xchange Forum 2018
Research Xchange Forum 2018 Insights Translation Solutions Trends and Challenges in Regenerative Medicine & Cell Therapy March 20 21, 2018 Sartorius Goettingen, Germany What to expect Learn about the latest
More informationSORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationUpdate from the Center for Biologics Evaluation and Research (CBER): Advancing the Development of Complex Biologic Products
Update from the Center for Biologics Evaluation and Research (CBER): Advancing the Development of Complex Biologic Products Peter Marks, M.D., Ph.D. FDLI 2017 Outline Products regulated Significance of
More informationFlow cytometry tools for characterization of GMP cell products
Flow cytometry tools for characterization of GMP cell products Alexandra Rizzitelli, PhD Project manager Cell therapies Pty Ltd, Melbourne, Australia What is product characterization? Identity (phenotype)
More informationImmunotherapy in myeloma
Immunotherapy in myeloma This Horizons Infosheet contains information on immunotherapy, a type of treatment being investigated in myeloma. The Horizons Infosheet series provides information relating to
More informationSORRENTO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event
More informationStrategies for Assessment of Immunotoxicology in Preclinical Drug Development
Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects
More informationCytomics in Action: Cytokine Network Cytometry
Cytomics in Action: Cytokine Network Cytometry Jonni S. Moore, Ph.D. Director, Clinical and Research Flow Cytometry and PathBioResource Associate Professor of Pathology & Laboratory Medicine University
More informationRegulatory Pathways for Rare Diseases
Regulatory Pathways for Rare Diseases Celia M. Witten, Ph.D., M.D. Deputy Director, FDA Center for Biologics Evaluation and Research Emerging Technologies for Rare Diseases: Clinical and Regulatory Case
More informationPlatelet Refractoriness: The Basics. Martin H. Bluth, MD, PhD
Platelet Refractoriness: The Basics Martin H. Bluth, MD, PhD Complete Toxicology Laboratories, LLC Objectives Define platelet refractoriness and associated conditions that may cause platelet refractoriness.
More informationManufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective
Manufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective CASSS CMC Summer Forum 2017 Chris Storbeck, PhD Health Canada Outline Health Canada organization Regulation of
More informationFlow CAST : Testing Potency and Efficacy of Inhibitors of PI3K δ, PI3Kγ, BTK and SYK Activity
Flow CAST : Testing Potency and Efficacy of Inhibitors of PI3K δ, PI3Kγ, BTK and SYK Activity Michele Romano, PhD Product Manager Flow CAST is for Research Use Only. Not for use in diagnostic procedures.
More informationThe promise of T cell engineering CD19 CAR therapy A prologue to immune regenerative medicine Vast potential, patience, public education
The promise of T cell engineering CD19 CAR therapy A prologue to immune regenerative medicine Vast potential, patience, public education Academies Cell Therapy Workshop Washington, October 13, 2016 Michel
More informationCell Therapy Services Your Product. Our Passion.
Pharma&Biotech Cell Therapy Services Your Product. Our Passion. Complete Portfolio of Services for cgmp Manufacturing of Cell-based Products Pharma&Biotech Cell Therapy Services for cgmp Manufacturing
More informationMeasurement of Hematopoietic Stem Cell Potency Prior to Transplantation
WHITE PAPER Measurement of Hematopoietic Stem Cell Potency Prior to Transplantation February, 2009 This White Paper is a forward-looking statement. It represents the present state of the art and future
More informationThe challenges of potency assay development for cell-based medicinal products in Europe
Focus Advanced therapies 5 The challenges of potency assay development for cell-based medicinal products in Europe Authors Valerie Pimpaneau, Senior Director, Voisin Consulting Life Sciences; François
More informationuniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B
uniqure Announces First Clinical Data From Second Dose Cohort of AMT-060 in Ongoing Phase I/II trial in Patients with Severe Hemophilia B -- Second-dose Cohort Demonstrates Dose Response with All Patients
More informationApplied Protein Services
Applied Protein Services Applied Protein Services A Window into the Future Development risk and attrition rates remain two of the greatest challenges to a successful biopharmaceutical pipeline. To help
More informationThe science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway
The science behind Betalutin : why is it unique? Roy H. Larsen PhD Sciencons AS, Oslo, Norway Speaker credentials Roy H. Larsen, PhD >25 years of experience in research on targeted radionuclide therapy
More informationAxel Hoos, M.D., Ph.D., SVP, Therapeutic Area Head for Oncology R&D and Head of Immuno Oncology, GSK
Magazine Article September 1, 2016 Source: Life Science Leader By Rob Wright, Chief Editor, Life Science Leader Follow Me On Twitter @RfwrightLSL Is Oncology Back At GSK? Did It Ever Leave? Axel Hoos,
More informationquantitate host cell DNA with high sensitivity and throughput resdnaseq Host Cell DNA Quantitation Systems: CHO, E.
quantitate host cell DNA with high sensitivity and throughput resdnaseq Host Cell DNA Quantitation Systems: CHO, E. coli, Vero, NS0 Precision counts Integrated real-time qpcr systems for quantitation of
More informationSupplementary Figure 1
Supplementary Figure 1 Supplementary Figure 1: Vector maps of TRMPV and TRMPVIR variants. Many derivatives of TRMPV have been generated and tested. Unless otherwise noted, experiments in this paper use
More informationAntibody-Drug Conjugate Bioanalytical Assay Development:
Antibody-Drug Conjugate Bioanalytical Assay Development: Immunogenicity Challenges November 16, 2016 Presented by Corinna Fiorotti, Ph.D. Presentation Overview ADC Overview ADC Assays ADC Immunogenicity
More informationIdentification of Critical Product Quality Attributes: Impact of Product Variants on Safety and Efficacy
Identification of Critical Product Quality Attributes: Impact of Product Variants on Safety and Efficacy Ziping Wei, Ph.D. Analytical Biochemistry MedImmune January 25, 2010 Outline Why do we need to identify
More informationResearch Xchange Forum 2018
Research Xchange Forum 2018 Insights Translation Solutions Trends and Challenges in Regenerative Medicine & Cell Therapy March 20 21, 2018 Sartorius Goettingen, Germany What to expect Learn about the latest
More informationConvoy TM Transfection Reagent
Convoy TM Transfection Reagent Catalog No.11103 0.25ml (40-80 transfections in 35mm dishes) Catalog No.11105 0.5 ml (80-165 transfections in 35mm dishes) Catalog No.11110 1.0 ml (165-330 transfections
More informationBIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE
The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential viral contaminants. Experience and knowledge in selecting
More informationOutsourcing and Partnering for Commercial Grade Manufacturing Frank Tufaro, Ph.D.
Outsourcing and Partnering for Commercial Grade Manufacturing Frank Tufaro, Ph.D. Should You Partner Manufacturing? $$$ versus Control 2 Ph. 1 Registration Trials Commercial Launch CMO CMO or Partner CMO
More informationUpdates to the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines)
Updates to the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines) Jacqueline Corrigan-Curay, J.D. M.D. Acting Director Office of Biotechnology Activities National Institute
More informationHow to overcome the challenges presented by bioassays
How to overcome the challenges presented by bioassays Tony Mire-Sluis Vice President, North America, Singapore, Abingdon, Contract and Product Quality Amgen Inc Why are Bioassays Considered so Difficult
More informationPaul Ashford Executive Director ICCBBA
Introduction to ISBT 128 Paul Ashford Executive Director ICCBBA ICCBBA ICCBBA enhances safety for patients by managing the ISBT 128 international information standard for use in transfusion and transplantation.
More informationREIMAGINING DRUG DEVELOPMENT:
Biology Reconstructed REIMAGINING DRUG DEVELOPMENT: Accurate Disease Modeling To Drive Successful Therapies Julia Kirshner, CEO julia@zpredicta.com 1 SUCCESS RATES OF DRUG DEVELOPMENT ARE LOW, " PARTICULARLY
More informationTumor immunotherapy by an engineering T cell receptor: a proposed hypothesis and study design
Available online at www.newresearch.co.in British Journal of Biomedical and Multidisciplinary Research (2017) 1(1):1-5 Tumor immunotherapy by an engineering T cell receptor: a proposed hypothesis and study
More informationAlphabetical Glossary of Terms. Gene Therapy & Immunotherapy for Cancer
Alphabetical Glossary of Terms Gene Therapy & Immunotherapy for Cancer Introduction The purpose of this glossary is to provide clarification of the most commonly used terms related to cancer research and
More informationCOMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES NON-AMPLIFIABLE IN EUKARYOTIC CELLS FOR VETERINARY USE
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Veterinary Use CVMP/IWP/07/98-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS NOTE FOR GUIDANCE 1 : DNA VACCINES
More informationxcelligence Immunotherapy Kit - B Cell Killing Assay ASSAY MANUAL
xcelligence Immunotherapy Kit - B Cell Killing Assay ASSAY MANUAL Table of Contents I. List of Kit Components 2 II. Storage Conditions 3 III. Additional Materials & Reagents Required 3 IV. Introduction
More informationAssembly Biosciences Jefferies 2015 Microbiome Summit. December 16, 2015
Assembly Biosciences Jefferies 2015 Microbiome Summit December 16, 2015 Forward-Looking Statements This presentation contains forward-looking statements regarding future events. Forward-looking statements
More informationGoldman Sachs Health Care Conference
Goldman Sachs Health Care Conference Laguna Niguel, California June 14, 2006 George Morrow Executive Vice President Global Commercial Operations Safe Harbor Statement This presentation contains forward-looking
More informationAgios Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event
More informationPassive Immunization Trials to Inform Vaccine Design
Passive Immunization Trials to Inform Vaccine Design Points for Consideration from deliberations held at the August 8, 2014 workshop Contents I. Introduction... 2 II. Types of trials... 2 1. Therapeutic
More informationValidation of an Endpoint Enzyme Activity Assay to Evaluate Potency for Lot Release and Stability Testing. Loc Vo, PhD
Validation of an Endpoint Enzyme Activity Assay to Evaluate Potency for Lot Release and Stability Testing Loc Vo, PhD Background: Enzyme replacement therapy for a lysosomal storage disease Timeline for
More informationDevelopment of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the application of the risk-based approach
3 July 2017 EMA/CAT/216556/2017 Inspections, Human Medicines, Pharmacovigilance and Committees Division Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the
More informationClinical and Operational Infrastructure for Engineered Cell Therapy Delivery
Clinical and Operational Infrastructure for Engineered Cell Therapy Delivery Sarah Nikiforow, MD, PhD Dana-Farber Cancer Institute Clinical Instructor, Stem Cell Transplantation Assistant Medical Director
More informationPhagocytosis Assay Kit (IgG FITC)
Phagocytosis Assay Kit (IgG FITC) Item No. 500290 Customer Service 800.364.9897 * Technical Support 888.526.5351 www.caymanchem.com TABLE OF CONTENTS GENERAL INFORMATION 3 Materials Supplied 4 Precautions
More informationTECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT
Specialist in tissue analysis by Histology, Immunohistochemistry and In Situ Hybridization TECHNOLOGIES & SERVICES FOR THERAPEUTIC ANTIBODY DEVELOPMENT CONTENTS Histalim: who we are Our areas of expertise
More informationRegulatory Review Considerations of Drug-Linker Quality in ADCs
Regulatory Review Considerations of Drug-Linker Quality in ADCs Xiao Hong Chen, Ph.D. Acting Quality Assessment Lead Division of New Drug Products I, Branch II ONDP/OPQ/CDER/FDA Outlines ADC IND submissions
More informationsirna Overview and Technical Tips
1 sirna Overview and Technical Tips 2 CONTENTS 3 4 5 7 8 10 11 13 14 18 19 20 21 Introduction Applications How Does It Work? Handy Tips Troubleshooting Conclusions Further References Contact Us 3 INTRODUCTION
More informationJustification of Specifications (JOS): What Product and Process Development was all About. Christopher A Bravery
Justification of Specifications (JOS): What Product and Process Development was all About Christopher A Bravery cbravery@advbiols.com 1 The Importance of Characterisation 2 http://www.advbiols.com/documents/importance
More informationExam MOL3007 Functional Genomics
Faculty of Medicine Department of Cancer Research and Molecular Medicine Exam MOL3007 Functional Genomics Tuesday May 29 th 9.00-13.00 ECTS credits: 7.5 Number of pages (included front-page): 5 Supporting
More informationDiscovery and Humanization of Novel High Affinity Neutralizing Monoclonal Antibodies to Human IL-17A
Discovery and Humanization of Novel High Affinity Neutralizing Monoclonal Antibodies to Human IL-17A Contacts: Marty Simonetti martysimonetti@gmail.com Kirby Alton kirby.alton@abeomecorp.com Rick Shimkets
More informationQuantification of Neutralizing Antibodies to Biopharmaceuticals using a Novel Cell- Bassed Assay Platform Technology
Quantification of Neutralizing Antibodies to Biopharmaceuticals using a Novel Cell- Bassed Assay Platform Technology Michael G Tovey, Director, Laboratory of Viral Oncology, Institut André Lwoff, Villejuif,
More informationCase Study: Examples Relating to the Quality Control of Cell-based Products
Case Study: Examples Relating to the Quality Control of Cell-based Products CMC Strategy Forum Japan 2014 Yuuki Miyatake1), 2) 1) TEIJIN PHARMA LIMITED 2) Japan Pharmaceutical Manufacturers Association
More informationAutomated Method for Determination of Infectious Dose (TCID 50 ) using Celigo Imaging Cytometer
Automated Method for Determination of Infectious Dose (TCID 50 ) using Celigo Imaging Cytometer Nexcelom Bioscience LLC. 360 Merrimack Street, Building 9 Lawrence, MA 01843 T: 978.327.5340 F: 978.327.5341
More informationGala s Gene Product Expression (GPEx ) Platform
Gala Biotech A Company with Gene Insertion and Manufacturing Technologies for the Next Generation of Gene Expression and Biologics Production Gala s Gene Product Expression (GPEx ) Platform Rapid creation
More informationViraDuctin Lentivirus Transduction Kit
Product Manual ViraDuctin Lentivirus Transduction Kit Catalog Number LTV-200 40 transductions (24-well plate) FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction The rate at which lentiviral
More informationReference Standards for Monoclonal Antibodies: Key Challenges Addressed
CASSS WCBP 2012: 16th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products January 23-25, 2012 Reference Standards for Monoclonal Antibodies: Key Challenges
More informationINTERIM RESULTS AS OF MARCH 31, 2017
INTERIM RESULTS AS OF MARCH 31, 2017 1 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of
More informationCurrent Best Practices in Commercial Kit Evaluation and Validation for Biomarker Assays
Current Best Practices in Commercial Kit Evaluation and Validation for Biomarker Assays 10th Workshop on Recent Issues in Bioanalysis, 2016 Paul Rhyne, Ph.D. - Director of Immunoassay Services Copyright
More informationComparability: Managing Process Changes. Christopher A Bravery
Comparability: Managing Process Changes Christopher A Bravery cbravery@advbiols.com 1 Introduction Why comparability is difficult What we are trying to achieve Why cells make this less certain Common mistakes
More informationFDA Perspectives On Viral & Vector Shedding Studies. Daniel Takefman, Ph.D. Chief, Gene Therapy Branch FDA/CBER ICH Workshop: October 31, 2007
FDA Perspectives On Viral & Vector Shedding Studies Daniel Takefman, Ph.D. Chief, Gene Therapy Branch FDA/CBER ICH Workshop: October 31, 2007 Overview Define shedding studies Outline basis for need of
More informationB-cell Epitope Prediction and Cloning monoclonal ADAs
B-cell Epitope Prediction and Cloning monoclonal ADAs Stefan Ryser, CEO, Trellis Bioscience 3 rd International Symposium on Higher Order Structure of Protein Therapeutics Arlington, Virginia, February
More informationINTELLIGENT ANTIBODY DISCOVERY FROM HUMANS AND OTHER ANIMALS. Guy Cavet
INTELLIGENT ANTIBODY DISCOVERY FROM HUMANS AND OTHER ANIMALS Guy Cavet g.cavet@atreca.com PRECISION THERAPIES FROM THE ACTIVE IMMUNE RESPONSE Patient/Animal with Immune Response Immune Repertoire Capture
More informationDeveloping an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL
Developing an Accurate and Precise Companion Diagnostic Assay for Targeted Therapies in DLBCL James Storhoff, Ph.D. Senior Manager, Diagnostic Test Development World Cdx, Boston, Sep. 10th Molecules That
More informationApplication of Quality Risk Management Tools for Cell Therapy Manufacturing
Application of Quality Risk Management Tools for Cell Therapy Manufacturing 17 th ISCT Annual Meeting May 20, 2011 Jean Stanton Associate Director, Product Quality Management Janssen Supply Chain Conflict/Disclaimer
More informationCHANGES TO A GENE THERAPY MEDICINAL PRODUCT: REGULATORY VIEWS
CHANGES TO A GENE THERAPY MEDICINAL PRODUCT: REGULATORY VIEWS Maria Cristina Galli, Ph.D. Istituto Superiore di Sanità Roma, Italy EATRIS ATMP platform chair ISCT 2016 Global Regulatory Perspective Workshop
More informationThe Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives
The Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products CDER/FDA CASSS, Applications of
More informationFor the quantitative detection of human IL6 in serum, plasma, cell culture supernatants and urine.
m andw da a For the quantitative detection of human IL6 in serum, plasma, cell culture supernatants and urine. general information Catalogue Number Product Name Species cross-reactivity Range (calibration
More informationICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3
European Medicines Agency June 2009 EMEA/CHMP/ICH/380636/2009 ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions Step 3 NOTE FOR GUIDANCE
More informationHSV-2 therapeutic vaccine program. Subunit vaccine candidates
HSV-2 therapeutic vaccine program Subunit vaccine candidates Our HSV-2 vaccine program Therapeutic subunit vaccine T-cell-based Aim: Best-in-class antigens by engineering Excellent standing (Sept 2017):
More informationInvestor Presentation Stellar Biotechnologies, Inc. Nasdaq: SBOT. February 7, 2018
Investor Presentation Stellar Biotechnologies, Inc. Nasdaq: SBOT February 7, 2018 Safe Harbor This presentation may contain forward-looking statements within the meaning of Section 27A of the Securities
More informationTransIT -Lenti Transfection Reagent
Quick Reference Protocol, SDS and Certificate of Analysis available at mirusbio.com/6600 INTRODUCTION Lentivirus is an enveloped, single-stranded RNA virus from the Retroviridae family capable of infecting
More informationThe Glue Grant: Inflammation and the Host Response to Injury
The Glue Grant: Inflammation and the Host Response to Injury Methods in Bioengineering Ronald G. Tompkins, M.D., Sc.D. John F. Burke Professor of Surgery Harvard Medical School Chief of Staff Shriners
More informationNanotechnology: A Brief History and Its Convergence with Medicine. Weston Daniel, PhD Director of Program Management
Nanotechnology: A Brief History and Its Convergence with Medicine Weston Daniel, PhD Director of Program Management Outline Introduction The Nanoscale Applications Realization of a Vision There s Plenty
More informationFDA Perspectives on Biomarkers. Steven Kozlowski, M.D. Office of Biotechnology Products OPS/CDER/FDA
FDA Perspectives on Biomarkers Steven Kozlowski, M.D. Office of Biotechnology Products OPS/CDER/FDA Importance of Biomarkers Earlier diagnosis Focusing expensive & invasive therapies on the right populations
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationWhat s the difference? Challenges in pre-clinical development of biologics
Biologics vs Small MW NCEs What s the difference? Challenges in pre-clinical development of biologics Peter Lloyd Joint Conference of EU Human Pharmacological Societies and 20 th Anniversary of AGAH 31
More informationLTX 109. BIO International Philadelphia 2015
LTX 109 BIO International Philadelphia 2015 Lytix Biopharma company background Established in 2003 to develop and commercialize medical applications of lytic peptides originating from the University of
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationSecond Quarter 2016 Financial Results. August 4, 2016
Second Quarter 2016 Financial Results August 4, 2016 Cautionary Note Regarding Forward-Looking Statements This presentation and various remarks we make during this presentation contain forward-looking
More informationFirst Annual Biomarker Symposium Quest Diagnostics Clinical Trials
First Annual Biomarker Symposium Quest Diagnostics Clinical Trials Terry Robins, Ph.D. Director Biomarker R&D and Scientific Affairs Quest Diagnostics Clinical Trials Key Considerations: Biomarker Development
More informationTechnical Review. Real time PCR
Technical Review Real time PCR Normal PCR: Analyze with agarose gel Normal PCR vs Real time PCR Real-time PCR, also known as quantitative PCR (qpcr) or kinetic PCR Key feature: Used to amplify and simultaneously
More informationFibrinogen Universal Kit
Order references Reagents CONT FITUR-B00 Universal kit 1 x 50 ml R1 + 1 x 5 ml R2 FITUR-00 Universal kit 2 x 50 ml R1 + 1 x 15 ml R2 FITUR-C00 Universal kit 2 x 17 ml R1 + 1 x 4 ml R2 Other necessary products
More informationMolecular Cell Biology - Problem Drill 11: Recombinant DNA
Molecular Cell Biology - Problem Drill 11: Recombinant DNA Question No. 1 of 10 1. Which of the following statements about the sources of DNA used for molecular cloning is correct? Question #1 (A) cdna
More informationGlobal Leader in Viral Vector Technologies
Global Leader in Viral Vector Technologies Gene Therapy Vaccines - Discovery 1 SIRION BIOTECH ANY GENE TO ANY CELL Expert for viral vectors Competitive proprietary viral vector platforms High-end enabling
More informationComplement C4 Universal Kit
Order references Reagents CONT C4TUR-B00 Universal kit 1 x 50 ml R1 + 1 x 5 ml R2 C4TUR-00 Universal kit 2 x 50 ml R1 + 1 x 15 ml R2 C4TUR-C00 Universal kit 1 x 12 ml R1 + 1 x 2 ml R2 Other necessary products
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationFacility and Equipment Maintenance
Facility and Equipment Maintenance Deborah L. Griffin Manager, Quality Assurance for Cellular Therapies Hillman Cancer Center University of Pittsburgh Cancer Institute University of Pittsburgh Medical
More informationAugust 2017 Changes. Flow Cytometry Checklist. CAP Accreditation Program
August 2017 Changes Flow Cytometry Checklist CAP Accreditation Program College of American Pathologists 325 Waukegan Road Northfield, IL 60093-2750 www.cap.org 08.21.2017 Disclaimer and Copyright Notice
More informationMouse ICAM-1 / CD54 ELISA Pair Set
Mouse ICAM-1 / CD54 ELISA Pair Set Catalog Number : SEK50440 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized in the General
More informationDeveloping T cell vaccines for HSV-2 Infection
Developing T cell vaccines for HSV-2 Infection Jessica Baker Flechtner, PhD World Vaccine Congress 24-26 March, 2014 Deep Pipeline of T Cell-Enabled Vaccine Candidates Discovery Pre-clinical Phase 1 Phase
More informationS9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers
S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers Current version dated 8 June 2016 International Council for Harmonisation of
More information